Podcast Episode 1: A Pragmatic Overview of Heart Failure in Patients with Diabetes for Endocrinologists, Primary Care Physicians and Noncardiologist Clinicians Authors: Nihar R. Desai, Silvio E. Inzucchi, Eugene E. Wright Published: 2026 ABSTRACT Heart failure is a growing major public health concern. Total medical costs for heart failure in the USA are expected to rise to more than US $70 billion by 2030, and this is expected to rise as the prevalence of heart failure increases owing to an aging population and the concurrent increase in risk factors for heart failure such as obesity, diabetes, and chronic kidney disease. Heart failure affects 22% of patients with type 2 diabetes and is frequently the first presentation of cardiovascular disease in these patients. One of the key challenges in heart failure treatment is early detection and diagnosis. Heart failure can present similarly to chronic obstructive pulmonary disease and is often misdiagnosed. Late diagnosis of heart failure can lead to delays in treatment initiation and poor patient outcomes. Clinicians other than specialist cardiologists, particularly endocrinologists and primary care physicians in the case of patients with diabetes, can play a key role in the early detection and diagnosis of heart failure. In this podcast series of three episodes, a cardiovascular specialist, an endocrinologist, and a primary care physician will provide practical guidance for primary care physicians on optimal identification and management of heart failure in patients with diabetes. In the first episode, we give a pragmatic overview of heart failure and practical guidance on how clinicians can identify patients most at risk of developing heart failure, tips for early detection and screening, and ultimately, how to prevent progression of heart failure in these patients. Podcast available for this articleSupplementary InformationThe online version contains supplementary material available at 10.1007/s13300-026-01855-7. Podcast Content The podcast video can be downloaded from the article’s Figshare page here: 10.6084/m9.figshare.31389532. Alternatively, you can stream the podcast by searching for ‘ADIS Journal Podcasts’ on your preferred podcast platform. Transcript Dr Nihar Desai [0:00:00] My name is Nihar Desai. I’m an Associate Professor of Medicine and Vice Chief for the Section of Cardiovascular Medicine at the Yale University School of Medicine in New Haven, CT. I’m a cardiovascular medicine specialist and pleased to be joined by my two outstanding colleagues, Dr Silvio Inzucchi and Dr Eugene Wright in the first of three podcasts, where we will discuss a practical approach to heart failure in patients with diabetes. In this first episode, we will discuss how clinicians can identify patients at risk of developing heart failure and ultimately how to prevent progression of heart failure in these patients. Dr Inzucchi and Dr Wright, please introduce yourselves to the audience. Dr Silvio Inzucchi [0:00:47] Well, thanks for inviting me. I’m Silvio Inzucchi. I’m the Clinical Chief of the Section of Endocrinology at Yale School of Medicine and Medical Director of the Yale Diabetes Center at Yale New Haven Hospital. I’ve had a long-standing interest in the impact of diabetes, and its treatment, on cardiovascular disease. Dr Eugene Wright [0:01:07] Thank you. I’m Eugene Wright. I’m a primary care internist with many years of practice experience. I’m also a Consulting Associate in the Department of Medicine at Duke University and serve as the Medical Director for Performance Improvement at the South Piedmont Area Health Education Center here in Charlotte, NC. Dr Nihar Desai [0:01:26] Well, thank you both for talking with me today. As we all know, heart failure is one of the largest public health issues in the USA. Prevalence continues to rise as the population ages, and therefore, the incidence of risk factors for heart failure such as hypertension, diabetes, and kidney disease will also increase [1, 2]. As an endocrinologist and a primary care physician, firstly, could you describe the typical patient with heart failure that you diagnose, and secondly, how common is it for you to see patients with undiagnosed heart failure in your practice? Dr Eugene Wright [0:02:01] Well, thank you. The typical patient with heart failure seen in primary care is over 60 years of age, more likely to be male and often a smoker. I think it’s worth mentioning that people from ethnic minority backgrounds, particularly the Black or African American ancestry, and low socioeconomic backgrounds, are more likely to develop heart failure [3–5]. The typical heart failure patient is also likely to have comorbidities such as hypertension, diabetes, and obesity. Obesity is a risk factor for developing hypertension and cardiovascular disease, which are common risk factors for developing heart failure [6], and it is also a risk factor for developing heart failure, independently of other cardiovascular risk factors [7]. On the second part of your question, it is increasingly common to see patients with unrecognized and undiagnosed heart failure in clinic, in part, due to the complexities of diagnosing patients with multiple comorbidities. For example, misdiagnosis or missed diagnosis of heart failure is common in patients with ischemic heart disease and lung disease [8]. Additionally, heart failure is under-recognized and often misdiagnosed as chronic obstructive pulmonary disease due to the overlapping symptoms [8]. Dr Silvio Inzucchi [0:03:24] I agree, Eugene. We probably see at least a patient each day who might have undiagnosed heart failure, or who is at risk of developing heart failure in the next year, often with multiple comorbidities. Heart failure is a common complication of diabetes; it’s prevalent in over one out of every five patients with type 2 diabetes [9]. Importantly, just having diabetes is considered Stage A of heart failure; and of course, diabetes worsens the clinical trajectory of individuals with heart failure [10]. Chronic kidney disease, or CKD, is another important comorbidity to consider with heart failure. Heart failure is present in up to half of patients with CKD, depending on the stage of the disease and the age of the patient [11]. Overlap between CKD and heart failure occurs due to interdependent physiological processes, including impaired renal hemodynamics, ischemic injury, progressive left ventricular remodeling, and ultimately cardiac dysfunction [12]. These disorders, along with obesity, can culminate into the so-called cardiovascular-kidney-metabolic syndrome or the CKM syndrome. Instead of considering cardiovascular, kidney, and metabolic conditions in isolation, it’s important for clinicians to recognize the interconnection between them [13]. Dr Nihar Desai [0:04:54] Yeah, I certainly agree with what both of you guys have introduced, and it’s clear that clinicians other than cardiologists are really key to the diagnosis and treatment of heart failure, certainly in the earlier stages of disease, and that greater education amongst physicians regarding risk factors for heart failure could lead to earlier diagnosis and greater opportunity to intervene, to then prevent progression of heart failure as well. Dr Eugene Wright [0:05:21] I think this really underscores the importance of early detection and screening. Heart failure is a progressive condition with poor prognosis [14], and patients with advanced stage heart failure have a greatly reduced quality of life [15]. By detecting and treating heart failure earlier and preventing or delaying progression of heart failure, there is a great opportunity to drastically improve the patients’ quality of life. A good resource for primary care physicians to determine what stage heart failure their patients have, that I’d like to highlight, is an infographic produced by Know Diabetes by Heart™, which is a collaborative initiative between the American Diabetes Association and the American Heart Association [16]. Dr Silvio Inzucchi [0:06:08] I agree, Eugene. I think this leads to something that might be underappreciated by both endocrinologists as well as primary care physicians: the very subtle presentation of heart failure, initially. As endocrinologists in our patients with type 2 diabetes, we can be focused on identifying or preventing atherosclerosis and symptomatic coronary artery disease, but actually the greater burden is heart failure. Heart failure can be the first presentation of cardiovascular disease in patients with type 2 diabetes [9]. Nihar, let me turn it back to you. As a cardiovascular specialist, what are the early signs that endocrinologists and primary care physicians can be looking out for to help with the early identification of heart failure in our patients? Dr Nihar Desai [0:06:54] Thanks, Silvio. I think a good place to start would be a very quick recap of the stages of heart failure.So, stage A refers to a patient who is at risk for heart failure. This is asymptomatic and, as you said earlier Silvio, includes patients with type 2 diabetes.Stage B is pre-heart failure. This includes people without symptoms of heart failure but with structural heart disease.Stage C is symptomatic heart failure, and stage D is advanced heart failure; so, people whose symptoms affect activities of daily living and who have repeated hospitalizations [17]. So, stage A refers to a patient who is at risk for heart failure. This is asymptomatic and, as you said earlier Silvio, includes patients with type 2 diabetes. So, stage A refers to a patient who is at risk for heart failure. This is asymptomatic and, as you said earlier Silvio, includes patients with type 2 diabetes. Stage B is pre-heart failure. This includes people without symptoms of heart failure but with structural heart disease. Stage B is pre-heart failure. This includes people without symptoms of heart failure but with structural heart disease. Stage C is symptomatic heart failure, and stage D is advanced heart failure; so, people whose symptoms affect activities of daily living and who have repeated hospitalizations [17]. Stage C is symptomatic heart failure, and stage D is advanced heart failure; so, people whose symptoms affect activities of daily living and who have repeated hospitalizations [17]. So, by the time your patient is presenting with symptoms of heart failure, such as shortness of breath, lower extremity edema, signs of congestion, they have likely already progressed to stage C. Heart failure is additionally classified according to left ventricular ejection fraction.Heart failure with a reduced ejection fraction, or HFrEF, is heart failure with a left ventricular ejection fraction of 40% or less.Heart failure with a preserved ejection fraction, or HFpEF, is when the ejection fraction is at least 50%.And an ejection fraction that’s between 40% and 50% is classified as heart failure with a mid-range or moderately reduced ejection fraction [17]. Heart failure with a reduced ejection fraction, or HFrEF, is heart failure with a left ventricular ejection fraction of 40% or less. Heart failure with a reduced ejection fraction, or HFrEF, is heart failure with a left ventricular ejection fraction of 40% or less. Heart failure with a preserved ejection fraction, or HFpEF, is when the ejection fraction is at least 50%. Heart failure with a preserved ejection fraction, or HFpEF, is when the ejection fraction is at least 50%. And an ejection fraction that’s between 40% and 50% is classified as heart failure with a mid-range or moderately reduced ejection fraction [17]. And an ejection fraction that’s between 40% and 50% is classified as heart failure with a mid-range or moderately reduced ejection fraction [17]. It should be noted, though, that these patients are likely to present with similar symptoms, such as fatigue, dyspnea, and edema. To your very good question, Silvio, what can we do to catch these patients earlier and maybe prevent progression of heart failure? I think the first thing we need to do is to recognize that patients with diabetes, obesity, hypertension, coronary disease, and others are at high risk for developing heart failure. Then we need to regularly screen these patients for the development and diagnosis of heart failure. Dr Eugene Wright [0:08:58] So, based on that, Nihar, now that we’ve identified the patient at high risk, as a primary care physician or a noncardiology specialist, what screening and testing should we be focusing on? Dr Nihar Desai [0:09:11] So, I think biomarkers are really important to support the detection of cardiac dysfunction at an early stage. Measurement of the natriuretic peptide or high sensitivity cardiac troponin on at least a yearly basis is recommended to identify the presence of early-stage heart failure [7, 9]. Assessing natriuretic peptides may be done more frequently, if there’s a change in clinical status or concern for heart failure emerges [9]. Natriuretic peptides are released from the heart and cleaved into the hormonally active B-type natriuretic peptide, or BNP, and the inactive N-terminal prohormone of BNP, or the NT-proBNP. Both BNP and NT-proBNP are viewed as comparable in their utility in detecting heart failure but differ in their circulating levels [18]. To determine heart failure risk, a useful cutoff value for BNP is over 50 pg/mL. For NT-proBNP, this is over 125 pg/mL, and for high sensitivity, cardiac troponin is over the 99th percentile for the healthy patient population [9]. Serial measurements and looking at biomarker levels as continuous variables have been shown in clinical trials to be a key tool in early detection of heart failure. I’ll give you one example from the EXAMINE trial in patients with type 2 diabetes, two NT-proBNP measurements spaced 6 months apart were able to identify risk for heart failure. Those with two elevated measurements were at highest risk and those patients with an increased measurement relative to baseline had rising risk for heart failure [19]. It’s also worth mentioning that biomarker results should be analyzed in the context of the complete clinical examination. Factors such as age, the presence of kidney disease or atrial fibrillation may lead to increased levels of these prognostic biomarkers without necessarily being an indication of progressing heart failure [20–22]. On the other hand, obesity may lower natriuretic peptide concentrations, even if there is significant risk of heart failure [23]. Dr Silvio Inzucchi [0:11:31] Nihar, what are your thoughts on risk scores like the TIMI Heart Failure Risk Score [24], the Health ABC Risk Score [25]? Are these tools practical for us to use in the clinical setting? Dr Nihar Desai [0:11:42] Yeah, it’s a great question, Silvio. I think they have some utility, I think it really depends. If you have a patient in the clinic and you’ve gone through step-by-step thorough medical history, physical examination, ruled out other potential causes for common heart failure symptoms such as edema (which can also indicate cirrhosis or nephrotic syndrome, thyroid disease, venous insufficiency, among many others) and then tested natriuretic peptides and biomarkers, then these are things that I would focus on. But risk scores can be good for understanding how risk factors such as diabetes, hypertension, and age can exacerbate heart failure and then support clinical decision-making. Dr Silvio Inzucchi [0:12:26] Which patients might qualify for an echocardiogram? Would you suggest performing an echo on every patient deemed to be at high risk for heart failure? Dr Nihar Desai [0:12:34] It’s a really good question. I think if you’ve identified a patient at high risk and they’ve had abnormal natriuretic peptide or cardiac troponin levels, at that point, echocardiography would be the next step to take. An echo, of course, will give you information on the cause of heart failure, any structural functional cardiac changes that have already occurred, and of course, will differentiate between HFrEF and HFpEF. But there’s no need to delay the initiation of pharmacological intervention while waiting to complete an echocardiogram. In the USA, we typically conduct laboratory testing and then refer for additional cardiac imaging (most commonly echocardiography) in the appropriate context. In other healthcare systems, and potentially in the future, as imaging becomes more point of care, one can envision a scenario where even more screening is done with echocardiography. Dr Eugene Wright [0:13:31] So, once we’ve identified our patient who is at high risk, we’ve confirmed with biomarker testing and an echocardiogram, moving forward, what are these patients at higher risk of? Dr Nihar Desai [0:13:44] There’s often an early period of stability for patients with heart failure, but we know that over time, there will be periods of decompensation and worsening symptoms with increased risk of hospitalization and death [26]. Earlier intervention, of course, can help to increase that period of asymptomatic clinical stability, and delay the onset and progression of heart failure. Dr Eugene Wright [0:14:07] So, we’ve come up with a nice stepwise approach here to help primary care physicians and endocrinologists detect and intervene in heart failure earlier. To summarize:Step 1: medical history and physical examination, looking out for diabetes, kidney disease, hypertension, and obesity to identify those at high risk for developing heart failure.Step 2: biomarker testing high-risk individuals at least annually so we can detect progression of heart failure as early as possible.Step 3: if biomarker testing is indicative of cardiac dysfunction, perform an echocardiograph.Step 4: initiate intervention as soon as possible to delay progression of heart failure. This should involve counseling the patient about what is being treated and why, and the need for lifestyle modifications like weight loss, smoking cessation, increased physical activity, as well as the importance of medication adherence. Step 1: medical history and physical examination, looking out for diabetes, kidney disease, hypertension, and obesity to identify those at high risk for developing heart failure. Step 1: medical history and physical examination, looking out for diabetes, kidney disease, hypertension, and obesity to identify those at high risk for developing heart failure. Step 2: biomarker testing high-risk individuals at least annually so we can detect progression of heart failure as early as possible. Step 2: biomarker testing high-risk individuals at least annually so we can detect progression of heart failure as early as possible. Step 3: if biomarker testing is indicative of cardiac dysfunction, perform an echocardiograph. Step 3: if biomarker testing is indicative of cardiac dysfunction, perform an echocardiograph. Step 4: initiate intervention as soon as possible to delay progression of heart failure. This should involve counseling the patient about what is being treated and why, and the need for lifestyle modifications like weight loss, smoking cessation, increased physical activity, as well as the importance of medication adherence. Step 4: initiate intervention as soon as possible to delay progression of heart failure. This should involve counseling the patient about what is being treated and why, and the need for lifestyle modifications like weight loss, smoking cessation, increased physical activity, as well as the importance of medication adherence. Dr Silvio Inzucchi [0:15:14] That’s a really nice summary, Eugene. I hope that noncardiologists listening to this can take away, first, how common heart failure is, particularly in patients with diabetes, CKD, and obesity; and second, the tools that are available to us so we can better screen for and identify heart failure in patients in our practices. Dr Nihar Desai [0:15:37] It’s a great point. I think Silvio, linked to that point, is really the importance of early detection and diagnosis to improve outcomes and prognosis for patients with heart failure. So, thank you so much Eugene and Silvio for joining me today. I look forward to talking with you more in our next episode. Join us for episode 2 of this podcast series where we will talk about guideline-directed medical therapy for heart failure, what pharmacological treatments are available for the prevention of heart failure progression, as well as the importance of lifestyle modifications for patients with heart failure and comorbidities such as diabetes, obesity, and hypertension.